Is Nurix Therapeutics, Inc. (NRIX) a good stock to buy?

Olyth's institutional analysis of NRIX reveals an Altman Z-Score of 3.06 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.08B most recent), help investors decide if NRIX fits their risk profile.

What is the current P/E ratio for NRIX?

As of the latest trading session, Nurix Therapeutics, Inc. (NRIX) has a trailing P/E ratio of -5.88.

Who is the CEO of Nurix Therapeutics, Inc.?

The current Chief Executive Officer of Nurix Therapeutics, Inc. is Arthur T. Sands.

What was NRIX's revenue for the last 5 years?

According to its latest income statements, Nurix Therapeutics, Inc. reported annual revenues of $0.08B (2025), $0.05B (2024), $0.08B (2023), $0.04B (2022), $0.03B (2021) respectively.

Does NRIX pay a dividend?

Nurix Therapeutics, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does NRIX have?

In its latest reporting period, Nurix Therapeutics, Inc. generated $-0.26B in Free Cash Flow against a total debt load of $0.06B.

What is the Price-to-Book (P/B) ratio of Nurix Therapeutics, Inc.?

The Price-to-Book (P/B) ratio for Nurix Therapeutics, Inc. (NRIX) is currently 2.89.

What is the Price-to-Sales (P/S) ratio of NRIX?

Based on trailing twelve-month data, Nurix Therapeutics, Inc. (NRIX) trades at a Price-to-Sales (P/S) ratio of 16.87.

What is Nurix Therapeutics, Inc.'s Return on Equity (ROE)?

Nurix Therapeutics, Inc. (NRIX) has a Return on Equity (ROE) of -57.51%, representing its profitability relative to shareholder equity.

NRIX

Nurix Therapeutics, Inc. · Healthcare

16.35

3.55%(+0.56)

16.90

3.36%(+0.55)

After Hours

Last Updated: — ET

52W L: $8.1852W H: $22.50

$16.35

CHG+1.45 (+9.73%)

H$16.88

L$13.50

VOL21M

NRIX (1h)

Company Profile

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

286

IPO Date

2020-07-24

Beta

1.98

Websitewww.nurixtx.com↗

NRIX

Nurix Therapeutics to Participate in Upcoming Investor Conference

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of “Moderate Buy” from Analysts

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight